small-molecule and a multitarget tki anlotinib (MultiTarget Pharmaceuticals)
90
Structured Review
MultiTarget Pharmaceuticals
small-molecule and a multitarget tki anlotinib
Small Molecule And A Multitarget Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+tki/anlotinib/pmc12198539-51-6-4
Average 90 stars, based on 1 article reviews
Small Molecule And A Multitarget Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+tki/anlotinib/pmc12198539-51-6-4
Average 90 stars, based on 1 article reviews
small-molecule and a multitarget tki anlotinib - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis"
Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis
Journal: Therapeutic Advances in Medical Oncology
doi: 10.1177/17588359251348310
Figure Legend Snippet: Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.
Techniques Used:
Figure Legend Snippet: HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.
Techniques Used:
Figure Legend Snippet: Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.
Techniques Used:
Related Articles
other:Article Title: An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Article Snippet: Introduction: The angiogenesis mechanism is considered a crucial point in neoplastic development.. A growing number of multi-targeted tyrosine kinase inhibitors (TKI) has been developed and approved for cancer treatment during the last few years.. Cardiac side effects still remain an issue to manage nowadays. Article Title: Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma Article Snippet: It acts as a Article Title: Targeted Glioma Therapy—Clinical Trials and Future Directions Article Snippet: NCT01100177 (April 2010–March 2013) , PDGFRα/β, c-Kit, VEGFR1/2/3, FLT3 and Clinical Proteomics:Article Title: Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges Article Snippet: Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of patients with advanced non–small cell lung cancer without driver genetic alterations.. Most of these patients, however, will experience disease progression within the first year after treatment initiation and both patients and their physicians will be confronted with the dilemma of the optimal second-line treatment.. Identification of molecular targets, such as KRASG12C, BRAFV600X,METexon14, and human epidermal growth factor receptor 2mutations, and RET rearrangements offer therapeutic opportunities in pretreated patients with corresponding alterations. DNA Synthesis:Article Title: Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021 Article Snippet: .. Fig. 5 FDA-approved therapeutic drugs for gastrointestinal cancers. a Distribution of therapeutic drugs for gastrointestinal cancers during the past 31 years (adapted from [ , ]). b Photosensitizer. c VEGFR2-directed mAb. |
